Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1.Provision of written informed consent prior to any study-related procedures/examinations 2.Aged 20 years and older 3.Subjects who are planned to undergo a non-emergent EGD or colonoscopy, including gastrointestinal endoscopic polypectomy that shall be completed within 1 hour (excluding the endoscopic submucosal dissection and ultrasonic endoscope, pernasal endoscope, etc.). Exclusion Criteria:~1. involvement in the planning and/or conduct of the study (applies to both sponsor's employees and/or staffs at the study site)~2. Subjects who underwent a endoscopic procedure under ICI35,868 (propofol) administration within 1 year.~3. Participation in another clinical study with an investigational product within 4 weeks prior to randomisation.~4. Baseline (Visit 1) of blood oxygen saturation (SpO2)\<90% (room air)~5. ASA III, IV, V and VI ; Subject with serious disease of cardiovascular, respiratory, renal, liver, pancreatic or endocrine function.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: PLACEBO_COMPARATOR): Group 1 (placebo group) is treated by Anaesthesiologist
- Group 2 (Type: ACTIVE_COMPARATOR): Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist
- Group 3 (Type: ACTIVE_COMPARATOR): Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist

Based on this trial design, predict the completion outcome and termination type (if applicable).